LCE1B: A Potential Drug Target and Biomarker for Ovarian Cancer

Target Name: LCE1B

NCBI ID: G353132

LCE1B

LCE1B: A Potential Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is the most common gynecological malignancy in the developed world, with over 21,000 new cases and 12,000 deaths in the United States alone in 2019. Despite advances in surgical and radiation treatments, the survival rate for ovarian cancer has remained relatively stagnant in recent years. Therefore, there is a need for new and effective treatments to improve outcomes.

Late cornified envelope protein 1B (LCE1B) is a protein that has been identified as a potential drug target and biomarker for ovarian cancer. LCE1B is a transmembrane protein that is expressed in various tissues, including ovarian epithelial, stromal, and perithelial cells. It is involved in the regulation of cell growth, apoptosis, and angiogenesis, and has been implicated in the development and progression of ovarian cancer.

Despite the promising potential of LCE1B as a drug target, much more research is needed to fully understand its role in ovarian cancer. In this article, we will review the current literature on LCE1B, including its expression and function in ovarian cancer, its potential as a drug target, and its potential as a biomarker.

Expression and Function of LCE1B in Ovarian Cancer

LCE1B is a well-established gene that has been shown to be expressed in various tissues, including ovarian epithelial, stromal, and perithelial cells. It is a transmembrane protein that is involved in the regulation of cell growth, apoptosis, and angiogenesis.

Studies have shown that LCE1B is involved in the development and progression of ovarian cancer. For example, LCE1B has been shown to be overexpressed in various types of ovarian cancer, including epithelial, endometrial, and clear cell carcinomas. Additionally, LCE1B has been shown to be involved in the regulation of cell apoptosis, as well as the formation of blood vessels in ovarian cancer.

In addition to its role in cancer development, LCE1B has also been shown to be involved in the regulation of cancer stem cells. For example, studies have shown that LCE1B can promote the self-renewal and survival of cancer stem cells, which are important for the development and progression of cancer.

Potential as a Drug Target

The potential of LCE1B as a drug target is based on its involvement in various cellular processes that are involved in cancer development and progression. LCE1B has been shown to be involved in the regulation of cell growth, apoptosis, angiogenesis, and the regulation of cancer stem cells. Therefore, it is a potential target for small molecules that can inhibit these processes.

One approach to targeting LCE1B is to use small molecules that can inhibit its activity in cell growth and apoptosis. For example, inhibitors of the angiogenic factor, PDGF-A, have been shown to be effective in inhibiting LCE1B-mediated angiogenesis in ovarian cancer. Additionally, inhibitors of LCE1B-regulated cell apoptosis, such as BH3-zip2, have also been shown to be effective in inhibiting the development of ovarian cancer.

Another approach to targeting LCE1B is to use small molecules that can inhibit its activity in the regulation of cancer stem cells. For example, inhibitors of the stem cell factor, GATA3, have been shown to be effective in inhibiting LCE1B-mediated self-renewal of cancer stem cells.

Potential as a Biomarker

In addition to its potential as a drug target, LCE1B is also a potential biomarker for ovarian cancer. The expression of LCE1B has been shown to be associated with the development and progression of ovarian cancer, and therefore, its levels can be used as a biomarker for ovarian cancer.

Studies have shown that LCE1B levels are significantly elevated in various types of ovarian cancer, including epithelial, endometrial, and clear cell carcinomas. Additionally, studies have shown that LCE1B levels can be used as a biomarker for the detection and prognosis of ovarian cancer. For example, higher LCE1B levels have been shown to be associated with poor prognosis in ovarian cancer patients.

Conclusion

In conclusion, LCE1B is a protein that has been shown to be involved in the development and progression of ovarian cancer. Its expression and function in various tissues make it a potential drug target and biomarker for ovarian cancer. Further research is needed to fully understand its role in cancer development and progression.

Protein Name: Late Cornified Envelope 1B

Functions: Precursors of the cornified envelope of the stratum corneum

The "LCE1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LCE1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets